Listing & Compliance Notices

HUMANIGEN, INC received a nasdaq noncompliance notice notice regarding board independence (rules 5605(b)(1), 5605(c)(2)).

“Continued Listing Rule or Standard; Transfer of Listing. As a result of the below-reported resignations of three members of the board of directors (the “Board”) of Humanigen, Inc. (the “Company”), the Company notified The Nasdaq Stock Market of the Company’s non-compliance with each of Nasdaq Rule 5605(b)(1), which requires a Nasdaq-listed company to have a board of directors comprised of a majority of independent directors; and Nasdaq Rule 5605(c)(2), which requires a Nasdaq-listed company to have an audit committee of the board of directors comprised of at least three independent directors”

Nabriva Therapeutics plc received a nasdaq delisting notice notice regarding stockholders equity (rules 5550(b)(1)).

“July 21, 2023, Nabriva Therapeutics plc (the “Company”) received a delisting determination letter (the “Determination Letter”) from The Nasdaq Stock Market LLC (“Nasdaq”). The Determination Letter indicated that, based on (i) the Company’s continued non-compliance with the Nasdaq Capital Market’s requirement to have a minimum stockholders’ equity of $2,500,000 under Nasdaq Listing Rule 5550(b)(1) (the “Rule”) and (ii) the Company’s confirmation that it did not intend to submit a plan to regain compliance with the Rule, the Company’s ordinary shares, nominal value $0.01 per share (the “Ordinary”

Bellerophon Therapeutics, Inc. received a nasdaq delisting notice notice regarding minimum bid price (rules 5550(a)(2)).

“July 19, 2023, Bellerophon Therapeutics, Inc. (the “Company”) was notified by the Listing Qualifications Department (the “Staff”) of The Nasdaq Stock Market LLC (“Nasdaq”) that in light of the Company’s previously disclosed workforce reduction plan and focus on exploring strategic alternatives, based upon the Staff’s belief that the Company is a “public shell” as that term is defined in Nasdaq Listing Rule 5101 and the Company’s non-compliance with the $1.00 bid price requirement set forth in Nasdaq Listing Rule 5550(a)(2), the Company would be delisted from The Nasdaq Capital Market at the op”

Bellerophon Therapeutics, Inc. received a nasdaq delisting notice notice regarding other (rules 5101).

“July 19, 2023, Bellerophon Therapeutics, Inc. (the “Company”) was notified by the Listing Qualifications Department (the “Staff”) of The Nasdaq Stock Market LLC (“Nasdaq”) that in light of the Company’s previously disclosed workforce reduction plan and focus on exploring strategic alternatives, based upon the Staff’s belief that the Company is a “public shell” as that term is defined in Nasdaq Listing Rule 5101 and the Company’s non-compliance with the $1.00 bid price requirement set forth in Nasdaq Listing Rule 5550(a)(2), the Company would be delisted from The Nasdaq Capital Market at the op”

OLENOX INDUSTRIES INC. received a nasdaq compliance regained notice regarding minimum bid price (rules 5550(a)(2)).

“July 20, 2023, Safe & Green Holdings Corp. (the “Company”) received a notice (the “Notification Letter”) from the Listing Qualifications Department (the “Staff”) of The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that the Staff has determined that for 10 consecutive business days, from July 6, 2023 to July 19, 2023, the closing bid price of the Company’s common stock has been at $1.00 per share or greater. Accordingly, the Staff has determined that the Company has regained compliance with Listing Rule 5550(a)(2) and has indicated that the matter is now closed. On July 21, 2023, th”

Mountain Crest Acquisition Corp. V received a nasdaq deficiency notice notice regarding other.

“May 18, 2023, Mountain Crest Acquisition Corp. V, a Delaware corporation (the “Company”), received a notice from the Nasdaq Stock Market LLC (“Nasdaq”), stating that the Company no longer satisfies the requirement to maintain a minimum of 1,100,000 publicly held shares (the “PHS Requirement”) for continued listing on The Nasdaq Global Market, according to the number of publicly held shares reported on its Form 8-K for May 12, 2023. The Company was provided 45 calendar days, or until July 3, 2023, to submit a plan to Nasdaq to regain compliance with the PHS Requirement. The Company submitted su”

Ault Disruptive Technologies Corp received a nyse_american deficiency notice notice regarding other (rules 1003(b)(i)(A), 1003(b)(i)(B)).

“Guide, which requires the Company to maintain a minimum of 300 public stockholders on a continuous basis (the “ Minimum Public Holders ”). According to the Staff, the Company has 188,875 shares publicly held by 296 public stockholders. According to the Letter and i n accordance with Section 1009 of the Company Guide , the Company has 30 calendar days from the date”

JOANN Inc. received a nasdaq deficiency notice notice regarding market value (rules 5450(b)(2)(A), 5450(b)(2)(C)).

“July 20, 2023 (the “Notice Date”), JOANN Inc. (the “Company”) received a written notice (the “Market Value Notice”) from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) that the Company is not in compliance with the requirement to maintain a minimum market value of listed securities of at least $50 million, as set forth in Nasdaq Listing Rule 5450(b)(2)(A) (the “Market Value Standard”), because the market value of the Company’s common stock (the “Common Stock”) was less than $50 million for 30 consecutive business days. Also on the Notice Date, the Company recei”

Marblegate Acquisition Corp. received a nasdaq deficiency notice notice regarding market value (rules 5450(b)(2)(C)).

“July 19, 2023, the Company received a written notice (the “ Notice ”) from the Listing Qualifications Department (the “ Staff ”) of The Nasdaq Stock Market LLC (“ Nasdaq ”) indicating that, for the preceding 30 consecutive business days, the Company’s Market Value of Publicly Held Shares (“ MVPHS ”) was below the $15 million minimum requirement for continued listing on The Nasdaq Global Market pursuant to Nasdaq Listing Rule 5450(b)(2)(C) (the “ MVPHS Requirement ”). This Notice has no immediate effect on the listing or trading of the Company’s common stock on The Nasdaq Global Market and the”

Vinco Ventures, Inc. received a nasdaq deficiency notice notice regarding other (rules 5605(b)(1), 5605(c)(2), 5605(d)(2)).

“July 14, 2023, Vinco Ventures, Inc.(the “Company”) received an Additional Staff Determination – Delinquency letter from Nasdaq. Due to the resignations of Richard Levychin, Lisa King and Brian Hart from the Company’s Board of Directors, the Company no longer complies with Nasdaq’s independent director, audit, and compensation committee requirements as set forth in Listing Rule 5605(b)(1) and 5605(c)(2) and 5605(d)(2). Accordingly, these matters serve as an additional basis for delisting the Company’s securities from The Nasdaq Stock Market. This letter also serves as formal notification that t”

ViewRay, Inc. received a nasdaq delisting notice notice regarding minimum bid price (rules 5450(a)(1)).

“July 17, 2023, ViewRay, Inc. (the “Company”) was notified by The Nasdaq Stock Market (“Nasdaq”) that the Company’s common stock will be delisted from the Nasdaq Global Select Market as a result of (i) its filing for protection under Chapter 11 of the U.S. Bankruptcy Code, and (ii) concerns regarding the Company’s ability to sustain compliance with the $1.00 per share minimum bid price requirement for continued inclusion on Nasdaq based on Listing Rule 5450(a)(1). Trading of the Company’s common stock will be suspended as of the open business on July 26, 2023, and Nasdaq will apply to the Secur”

ViewRay, Inc. received a nasdaq delisting notice notice regarding other (rules 5450(a)(1)).

“July 17, 2023, ViewRay, Inc. (the “Company”) was notified by The Nasdaq Stock Market (“Nasdaq”) that the Company’s common stock will be delisted from the Nasdaq Global Select Market as a result of (i) its filing for protection under Chapter 11 of the U.S. Bankruptcy Code, and (ii) concerns regarding the Company’s ability to sustain compliance with the $1.00 per share minimum bid price requirement for continued inclusion on Nasdaq based on Listing Rule 5450(a)(1). Trading of the Company’s common stock will be suspended as of the open business on July 26, 2023, and Nasdaq will apply to the Secur”

Tenon Medical, Inc. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5550(a)(2), 5810(c)(3)(A)).

“ule 5550(a)(2) (the “Bid Price Rule”). Pursuant to Nasdaq Listing Rule 5810(c)(3)(A), the Company was provided an initial”

ALKALINE WATER Co INC received a nasdaq deficiency notice notice regarding late filing (rules 5250(c)(1)).

“July 18, 2023, The Alkaline Water Company Inc. (the "Company") received a deficiency letter (the "Letter") from the Listing Qualifications Department of The Nasdaq Stock Market (the "Nasdaq"), notifying the Company that since the Company had not yet filed its Form 10-K for the year ended March 31, 2023 (the "Form 10-K"), it no longer complies with the Nasdaq's Listing Rule 5250(c)(1) (the "Rule") relating to the Company's obligation to file periodic financial reports for continued listing. The Letter stated that the Company has 60 calendar days to submit a plan (the "Plan") to regain complianc”

RiskOn International, Inc. received a nasdaq deficiency notice notice regarding stockholders equity (rules 5550(b)(1)).

“July 18, 2023, BitNile Metaverse, Inc., a Nevada corporation (the “ Company ”) received a letter (the “ Letter ”) from the Listing Qualifications staff (the “ Staff ”) of the Nasdaq Stock Market LLC (“ Nasdaq ”) indicating that the Company’s stockholders’ equity as reported in its Annual Report on Form 10-K for the fiscal year ended March 31, 2023 (the “ Form 10-K ”), did not satisfy the continued listing requirement under Nasdaq Listing Rule 5550(b)(1) for the Nasdaq Capital Market, which requires that a listed company’s stockholders’ equity be at least $2.5 million. As reported on its Form 1”

Evoke Pharma Inc received a nasdaq extension granted notice regarding stockholders equity (rules 5550(b)(1)).

“July 19, 2023, Nasdaq notified the Company that it has granted the Company an extension until November 20, 2023 to regain compliance. Under the terms of the extension, the Company must provide to the Nasdaq staff a publicly available report that evidences such compliance and otherwise comply with conditions included in the extension notice. If the Company fails to evidence compliance upon filing the Company’s Annual Report on Form 10-K for the year ended December 31, 2023 with the Securities and Exchange Commission and Nasdaq, the Company may be subject to delisting from the Nasdaq Capital Mar”

Dare Bioscience, Inc. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5550(a)(2)).

“July 19, 2023, Daré Bioscience, Inc. (“Daré”) received a letter from the Listing Qualifications Department (the “Staff”) of the Nasdaq Stock Market (“Nasdaq”) notifying Daré that, for the last 30 consecutive business days, the closing bid price for Daré’s common stock was below the minimum $1.00 per share requirement for continued listing on The Nasdaq Capital Market as set forth in Nasdaq Listing Rule 5550(a)(2) (the “Minimum Bid Price Requirement”). The Nasdaq letter has no immediate effect on the listing of Daré’s common stock on the Nasdaq Capital Market. In accordance with Nasdaq listing”

NextPlay Technologies Inc. received a nasdaq deficiency notice notice regarding late filing (rules 5250(c)(1)).

“Nasdaq may grant an exception of up to 180 calendar days from the Form 10-K’s due date, or until November 27, 2023, to regain compliance. If Nasdaq does not accept the Company’s plan, then the Company will have the opportunity to appeal that decision to a Nasdaq Hearings Panel under Nasdaq Listing Rule 5815. The Company currently intends to submit a plan by August 7, 2023, the deadline, to Nasdaq that outlines, as definitively as possible, the steps the Company will take to promptly file the Form 10-K and the Form 10-Q and regain compliance. If the Company does not regain compliance within th”

Singular Genomics Systems, Inc. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5450(a)(1)).

“July 17, 2023, Singular Genomics Systems, Inc. (the “Company”) received a deficiency letter (the “Letter”) from The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that, for the preceding 30 consecutive business days prior to the date of the Letter, the bid price for the Company’s common stock (the “Common Stock”) closed below the $1.00 per share minimum bid price requirement for continued inclusion on the Nasdaq Global Select Market pursuant to Nasdaq Listing Rule 5450(a)(1) (the “Minimum Bid Price Requirement”). The Letter is a notice of deficiency, and not delisting, and has no imm”

Pasithea Therapeutics Corp. received a nasdaq extension granted notice regarding minimum bid price (rules 5550(a)(2), 5810(c)(3)(A)).

“July 19, 2023, the Company received a letter from Nasdaq advising that the Company had been granted a 180-day extension to January 15, 2024, to regain compliance with the Minimum Bid Price Requirement. The Company will continue to monitor the closing bid price of its Common Stock and may, if appropriate, consider implementing available options, including but not limited to, implementing a reverse stock split of its outstanding securities, to regain compliance with the Minimum Bid Price Requirement. If the Company does not regain compliance within the allotted compliance period, Nasdaq will pro”

AEye, Inc. received a nasdaq extension granted notice regarding minimum bid price (rules 5550(a)(2), 5810(c)(3)(A)).

“July 20, 2023, the Company was notified by Nasdaq that the Company had been granted a second 180-calendar day period, or until January 16, 2024 (the “Second Compliance Date”), to regain compliance and cure the deficiency, provided that the Company continues to meet the continued listing requirements of Nasdaq, other than the Bid Price Rule. This action has no immediate effect on the Company’s Nasdaq listing and its common stock will continue to be listed under the symbol “LIDR.” If the Company does not regain compliance with the Bid Price Rule prior to the Second Compliance Date, Nasdaq is exp”

vTv Therapeutics Inc. received a nasdaq extension granted notice regarding minimum bid price.

“July 17, 2023, the Company received notice from Nasdaq that, based upon the completed questionnaire and the expedited review process, it had approved the Company’s request to extend the period for the Company to regain compliance with the Minimum Bid Requirement until December 18, 2023. Nasdaq noted that the extension was based upon the Company’s representation that it would complete a reverse stock split no later than November 22, 2023, at a ratio between 1:10 and 1:20, and that it would obtain stockholder approval for such a reverse stock split on or before October 30, 2023. There can be no”

Staffing 360 Solutions, Inc. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5550(a)(2), 5810(c)(3)(A)).

“July 17, 2023, Staffing 360 Solutions, Inc. (the “Company”) received a letter from the Listing Qualifications Department of the Nasdaq Stock Market (“Nasdaq”) indicating that, based upon the closing bid price of the Company’s common stock for the 30 consecutive business day period between June 1, 2023, through July 14, 2023, the Company did not meet the minimum bid price of $1.00 per share required for continued listing on the Nasdaq Capital Market pursuant to Nasdaq Listing Rule 5550(a)(2). The letter also indicated that the Company will be provided with a compliance period of 180 calendar da”

KIORA PHARMACEUTICALS INC received a nasdaq deficiency notice notice regarding minimum bid price (rules 5550(a)(2), 5810(c)(3)(A)).

“July 18, 2023, Kiora Pharmaceuticals, Inc. (the “Company”) received a deficiency letter (the “Notice”) from the Listing Qualifications Department (the “Staff”) of The Nasdaq Stock Market, LLC (“Nasdaq”) notifying the Company that, for the last 30 consecutive business days, the bid price for the Company’s common stock had closed below $1.00 per share, which is the minimum closing price required to maintain continued listing on The Nasdaq Capital Market under Nasdaq Listing Rule 5550(a)(2) (the “Minimum Bid Requirement”). The Notice has no immediate effect on the listing of the Company’s common”

ALPINE SUMMIT ENERGY PARTNERS, INC. received a nasdaq delisting notice notice regarding other (rules 5101, 5110(b), IM-5101-1).

“July 12, 2023, the Company received written notice (the " Delisting Notice ") from the staff of The Nasdaq Stock Market LLC (" Nasdaq ") notifying the Company that, as a result of the Chapter 11 Cases and in accordance with Nasdaq Listing Rules 5101, 5110(b) and IM-5101-1, the staff of Nasdaq has determined that the Company's Class A Subordinate Voting Shares will be delisted from The Nasdaq Stock Market. In the Delisting Notice, the staff of Nasdaq referenced the Chapter 11 Cases and associated public interest concerns raised by them, concerns regarding the residual equity interest of the exi”

Aridis Pharmaceuticals, Inc. received a nasdaq delisting notice notice regarding other.

“July 17, 2023, Aridis Pharmaceuticals, Inc. (the “Company”) received written notice (the “ Notice ”) from the Nasdaq Stock Market, LLC (“ Nasdaq ”) that it would delist the Company’s shares of common stock from the Nasdaq Capital Market upon the opening of trading on July 19, 2023. The Company’s common stock will be traded on the OTC Pink Sheets and the Company will seek to establish relationships with market makers to provide additional trading opportunities in the Company’s stock. However, there can be no assurance that a market for the Company’s shares will develop. - 2 - SIGNATURES Pursuan”

9 METERS BIOPHARMA, INC. received a nasdaq delisting notice notice regarding other (rules 5101, 5110(b), IM-5101-1, 5550(b)(1), 5550(a)(2)).

“July 17, 2023, the Company entered the Bankruptcy Filing and the associated public interest concerns raised by such filing; (ii) concerns regarding the residual equity interest of the existing listed securities holders; and (iii) concerns about the Company’s ability to sustain compliance with all requirements for continued listing on Nasdaq, including the Company’s failure to comply with (a) the minimum $2,500,000 stockholders’ equity requirement under Listing Rule 5550(b)(1) and (b) the minimum bid price requirement under Listing Rule 5550(a)(2), pursuant to the notice received by the Company”

Wheeler Real Estate Investment Trust, Inc. received a nasdaq deficiency notice notice regarding audit committee (rules 5605).

“July 12, 2023, the Company received a letter from the listing qualifications staff of The Nasdaq Stock Market LLC (“ Nasdaq ”) notifying the Company that because the Audit Committee now only has two members, the Company no longer complies with the requirement set forth in the Nasdaq Listing Rule 5605 (the “ Rule ”) that the Audit Committee consist of at least three members . The Company is required to appoint a third member to its Audit Committee by the earlier of the Company’s next annual stockholders’ meeting or June 2, 2024. The Company expects to make the appointment within the time period”

FIREFLY NEUROSCIENCE, INC. received a nasdaq deficiency notice notice regarding stockholders equity.

“June 2, 2023 WaveDancer, Inc. (the “Company”) was notified by The Nasdaq Stock Market LLC (“Nasdaq”) that it was out of compliance with Nasdaq’s continued listing requirements because as of March 31, 2023, our reported stockholders’ equity of $2,371,318 was below the minimum requirement of $2,500,000. Under Nasdaq rules, the Company had 45 days, or until July 10, 2023, to submit a plan to regain compliance. In our June 8, 2023 Form 8-K, the Company disclosed its intention to timely request a hearing before the Nasdaq Hearings Panel (the “Panel”) to present its plan for regaining compliance wit”

Sphere 3D Corp. received a nasdaq compliance regained notice regarding minimum bid price (rules 5550(a)(2)).

“July 14, 2023, the Company received written notice from Nasdaq informing the Company that it has regained compliance with Rule 5550(a)(2) and this matter is now closed. On July 17, 2023, the Company issued a press release disclosing the listing notification letter from Nasdaq. The information contained in the press release is incorporated herein by reference and furnished as Exhibit 99.1.”

NVN Liquidation, Inc. received a nasdaq delisting notice notice regarding other (rules 5101, 5110(b), IM-5101-1).

“July 17, 2023, Novan, Inc. (the “Company”) filed a voluntary petition for relief under Chapter 11 of the United States Bankruptcy Code in the United States Bankruptcy Court for the District of Delaware. The case will be administered under the caption In re: Novan, Inc. et al , Case No. 23-10937. On July 17, 2023, the Company received written notice (the “Delisting Notice”) from the listing qualifications department staff of The Nasdaq Stock Market (“Nasdaq”) notifying the Company that, in accordance with Nasdaq Listing Rules 5101, 5110(b), and IM-5101-1, the staff of Nasdaq has determined that”

COMSCORE, INC. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5450(a)(1)).

“July 11, 2023, comScore, Inc. (the "Company") received a standard letter (the "Notification Letter") from The Nasdaq Stock Market LLC ("Nasdaq") stating that the Company was not in compliance with the minimum bid price requirements set forth in Nasdaq Listing Rule 5450(a)(1) because the Company's common stock did not maintain a minimum closing bid price of $1.00 per share for 30 consecutive business days. The Notification Letter has no immediate effect on the listing of the Company's common stock on Nasdaq. The Notification Letter provides that the Company has an automatic period of 180 calend”

Aspira Women's Health Inc. received a nasdaq deficiency notice notice regarding market value (rules 5550(b)(2), 5810(c)(3)(C)).

“July 11, 2023, Aspira Women’s Health Inc. (the “Company”) received written notice (the “Notice”) from the Listing Qualifications Staff (the “Staff”) of the Nasdaq Stock Market, LLC (“Nasdaq”) notifying the Company that for the last 30 consecutive business days prior to the date of the Notice, the Company’s minimum Market Value of Listed Securities was below the minimum of $35 million required for continued listing on the Nasdaq Capital Market pursuant to Nasdaq Listing Rule 5550(b)(2) (the “MVLS Requirement”). In accordance with Nasdaq Listing Rule 5810(c)(3)(C), Nasdaq has provided the Compan”

Enlightify Inc. received a nyse deficiency notice notice regarding shareholders.

“received a notification letter from the New York Stock Exchange (the “NYSE”) indicating that, the Company was noncompliant with Section 302 of the NYSE Listed Company Manual since the Company had not yet held an annual meeting of stockholders within twelve months of the end of the Company’s fiscal year ended June 30, 2022. The Company prepares to hold the annual meeting of stockholders for the fiscal year ended June 30, 2022 in the next few months which is required to bring it into compliance. 1 SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has d”

GAXOS.AI INC. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5550(a)(2)).

“July 10, 2023, The NFT Gaming Company, Inc. (the “Company”) received written notice (the “Notice”) from the Nasdaq Stock Market, LLC (“Nasdaq”) indicating that the bid price for the Company’s common stock (the “Common Stock”), for the last 30 consecutive business days, had closed below the minimum $1.00 per share and, as a result, the Company is not in compliance with the $1.00 minimum bid price requirement for the continued listing on The Nasdaq Capital Market, as set forth in Nasdaq Listing Rule 5550(a)(2). The Notice has no effect at this time of the Common Stock, which continues to trade o”

Genesis Growth Tech Acquisition Corp. received a nasdaq delisting notice notice regarding late filing (rules 5250(c)).

“July 14, 2023, Genesis Growth Tech Acquisition Corp. (the “ Company ”), received a written notice from the Listing Qualifications Department of The Nasdaq Stock Market (“ Nasdaq ”) indicating that the Company’s securities (units, ordinary shares and warrants) will be suspended from The Nasdaq Global Market on July 25, 2023, due to the Company’s non-compliance with Listing Rule 5452. Listing Rule 5452 requires that special purpose acquisition companies (SPACs) which listed their securities on The Nasdaq Global Market under alternative Listing Rule 5406, to among other things, maintain a minimum”

Genesis Growth Tech Acquisition Corp. received a nasdaq delisting notice notice regarding market value (rules 5452).

“listed their securities on The Nasdaq Global Market under alternative Listing Rule 5406, to among other things, maintain a minimum average market value of listed securities of $50,000,000, and a minimum average market value of publicly held shares of $40,000,000, over 30 consecutive trading days. Pursuant to the July 14, 2023, notice, Nasdaq advised the Company that”

Nogin, Inc. received a nasdaq deficiency notice notice regarding market value (rules 5450(b)(2)(C)).

“July 10, 2023, Nogin, Inc. (the “Company”) received a letter (the “Letter”) from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that, for the last 30 consecutive business days prior to the date of the Letter, the Company’s Market Value of Publicly Held Shares (“MVPHS”) was below the $15 million minimum requirement for continued listing on the Nasdaq Global Market under Nasdaq Listing Rule 5450(b)(2)(C) (the “Listing Rule”). The Letter is only a notification of deficiency, not of imminent delisting, and has no current effect on the listing”

Industrial Tech Acquisitions II, Inc. received a nasdaq deficiency notice notice regarding market value (rules 5550(b)(2), 5550(b)(1), 5550(b)(3)).

“July 10, 2023, Industrial Tech Acquisitions II, Inc., a Delaware corporation (the “ Company ” or “ ITAQ ”) received a deficiency notice from the Listing Qualifications Department (the “ Staff ”) of The Nasdaq Stock Market LLC (“ Nasdaq ”) notifying the Company that for the last 37 consecutive business days, the Company’s Market Value of Listed Securities (“ MVLS ”) was below the minimum of $35 million required for continued listing on The Nasdaq Capital Market pursuant to Nasdaq Listing Rule 5550(b)(2) (the “ Market Value Standard ”). This notification has no immediate effect on the listing or”

Sharps Technology Inc. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5550(a)(2)).

“July 12, 2023, Sharps Technology, Inc. (the “Company”) received a notice (the “Notice”) from the staff of the Listing Qualifications Department (the “Staff”) of The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that it was not in compliance with Nasdaq Listing Rule 5550(a)(2) (the “Rule”) because it failed to maintain a minimum bid price of $1.00 over the previous 30 consecutive business days dated May 26, 2023 to July 11, 2023. The Rules provide the company a compliance period of 180 calendar days in which to regain compliance. If at any time during this 180 day period the closing”

Canopy Growth Corp received a nasdaq deficiency notice notice regarding minimum bid price (rules 5450(a)(1)).

“July 11, 2023, Canopy Growth Corporation (the “Company”) received written notice (the “Letter”) from the Listing Qualifications Department of the Nasdaq Stock Market LLC (“Nasdaq”) informing the Company that it is not in compliance with Nasdaq Listing Rule 5450(a)(1), as the closing bid price of the Company’s common shares (the “Common Shares”) listed on The Nasdaq Global Select Market has been below $1.00 per share for the 30 consecutive business days prior to the date of the Letter (the “Minimum Bid Price Requirement”). The Letter has no immediate effect on the listing or trading of the Comm”

Edgewise Therapeutics, Inc. received a nasdaq deficiency notice notice regarding audit committee (rules 5605(c)(2), 5605(c)(4)).

“July 10, 2023, Edgewise Therapeutics, Inc. (the “Company”) received a notice (the “Notice”) from The Nasdaq Stock Market LLC (the “Nasdaq”) stating that, as a result of the resignation of Kenneth Harrison, Ph.D. (the “Director Resignation”) from the Board of Directors of the Company (the “Board”) and the Audit Committee of the Board (the “Audit Committee”), effective June 19, 2023 (as previously disclosed), the Company is no longer in compliance with the Nasdaq Listing Rule 5605, including the Nasdaq Listing Rule 5605(c)(2), which requires the Audit Committee to consist of at least three membe”

Spyre Therapeutics, Inc. received a nasdaq extension granted notice regarding minimum bid price (rules 5450(a)(1)).

“July 13, 2023, the Company received approval from Nasdaq of the Transfer (the “Approval”). The Transfer became effective at the opening of business on July 14, 2023. The Company’s Common Stock continues to trade under the symbol “AGLE.” The Nasdaq Capital Market operates in substantially the same manner as the Nasdaq Global Market, but with less stringent listing requirements, although listed companies must meet certain financial requirements and comply with Nasdaq’s corporate governance requirements. In connection with the Approval, the Company has been granted an additional 180-calendar day”

Singularity Future Technology Ltd. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5605(c)(4), 5605).

“July 13, 2023, Singularity Future Technology Ltd. (the “Company” or the “Registrant”) received a notice from The Nasdaq Stock Market LLC (“Nasdaq”) stating that the Company no longer complies with Nasdaq’s independent director and audit committee requirements under Nasdaq’s Listing Rule 5605 following the resignation of Tieliang Liu from the Company’s board of directors and audit committee effective July 3, 2023. Nasdaq advised the Company that in accordance with Nasdaq’s Listing Rule 5605(c)(4), the Company has a cure period to regain compliance (1) until the earlier of the Company’s next ann”

Singularity Future Technology Ltd. received a nasdaq deficiency notice notice regarding audit committee (rules 5605(c)(4)).

“July 13, 2023, Singularity Future Technology Ltd. (the “Company” or the “Registrant”) received a notice from The Nasdaq Stock Market LLC (“Nasdaq”) stating that the Company no longer complies with Nasdaq’s independent director and audit committee requirements under Nasdaq’s Listing Rule 5605 following the resignation of Tieliang Liu from the Company’s board of directors and audit committee effective July 3, 2023. Nasdaq advised the Company that in accordance with Nasdaq’s Listing Rule 5605(c)(4), the Company has a cure period to regain compliance (1) until the earlier of the Company’s next ann”

ABVC BIOPHARMA, INC. received a nasdaq extension granted notice regarding stockholders equity (rules 5550(b)(1)).

“July 10, 2023,Nasdaq granted the Company an extension to comply with Listing Rule 5550(b)(1). The Company must now achieve compliance with this rule on or before August 31, 2023. If the Company fails to evidence compliance upon filing its periodic report for the quarter ending September 30, 2023, the Company may be subject to delisting. If Nasdaq determines to delist the Company’s securities, the Company will have an opportunity to appeal Nasdaq’s decision. At this time, the Company’s Common Stock will continue to trade on The Nasdaq Capital Market under the symbol “ABVC”. SIGNATURE Pursuant t”

Mobiquity Technologies, Inc. received a nasdaq hearing update notice regarding minimum bid price (rules 5550(a)(2)).

“July 13, 2023, the Company received a letter from the Nasdaq Stock Market that the Company’s failure to meet the minimum bid price will be considered at its upcoming hearing at which time the Company will present a plan to both meet the minimum bid price and to meet the minimum $2.5 million stockholders’ equity requirement for continued listing. In the interim, the Company’s common stock will continue to trade on Nasdaq under the symbol “ MOBQ ” and our common stock purchase warrants will continue to trade on Nasdaq under the symbol “MOBQW” at least pending the ultimate conclusion of the heari”

BIO KEY INTERNATIONAL INC received a nasdaq extension granted notice regarding minimum bid price (rules 5550(a)(2)).

“July 12, 2023, the Company received a letter from Nasdaq (the “Letter”) stating that although the Company had not regained compliance with the Bid Price Rule, Nasdaq determined that the Company is eligible for an additional 180-day period, or until January 8, 2024, to regain compliance with the Bid Price Rule. In the Letter, Nasdaq stated that its determination was based on (i) the Company meeting the continued listing requirement for market value of its publicly held shares and all other applicable requirements for initial listing on the Nasdaq Capital Market with the exception of the minimum”

RiceBran Technologies received a nasdaq deficiency notice notice regarding audit committee (rules 5605, 5605(a)(2), 5605(c)(4)).

“July 10, 2023, RiceBran Technologies (the “Company”) received a notice (the “Notice”) from the Listing Qualifications Department (the “Staff”) of The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that, due to Jean M. Heggie’s previously disclosed resignation from the Company’s Board of Directors (the “Board”), the Company is not in compliance with Nasdaq’s audit committee composition requirements, as set forth in Nasdaq Listing Rule 5605, which requires that the Audit Committee of the Board (the “Audit Committee”) be comprised of at least three “independent directors” (as defined in”

ATOSSA THERAPEUTICS, INC. received a nasdaq compliance regained notice regarding minimum bid price (rules 5550(a)(2)).

“July 13, 2023, Atossa Therapeutics, Inc. (the “Company”) received a letter from The Nasdaq Stock Market LLC (“Nasdaq”) informing the Company that it had regained compliance with the minimum closing bid price requirement under Nasdaq Listing Rule 5550(a)(2) for continued listing on The Nasdaq Capital Market. As previously disclosed, on October 5, 2022, the Company was notified by Nasdaq that it was not in compliance with Nasdaq Listing Rule 5550(a)(2) because its common stock failed to maintain a minimum closing bid price of $1.00 per share for 30 consecutive business days. The Company was init”